DXR Stock Summary and Trading Ideas (Daxor - Closed End | NASDAQ:DXR)

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Daxor - Closed End trades on the NASDAQ stock market under the symbol DXR.

As of January 6, 2026, DXR stock price declined to $13.68 with 480 million shares trading.

DXR has a market cap of $66.15 million. This is considered a Micro Cap stock.

In the last 3 years, DXR traded as high as $14.76 and as low as $6.55.

The top ETF exchange traded funds that DXR belongs to (by Net Assets): VTI.

DXR has outperformed the market in the last year with a price return of +76.1% while the SPY ETF gained +18.1%. However, in the short term, DXR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -1.6% vs +3.7% return in SPY. But in the last 2 weeks, DXR shares have fared better than the market returning +8.4% compared to SPY +1.0%.

DXR support price is $13.64 and resistance is $15.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DXR shares will trade within this expected range on the day.